Frank Bedu-Addo - 02 Dec 2022 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role: President/CEO, Director
Signature: /s/ Frank Bedu-Addo
Issuer symbol: PDSB
Transactions as of: 02 Dec 2022
Net transactions value: -$270,955
Form type: 4
Filing time: 02 Dec 2022, 15:47:14 UTC
Previous filing: 20 Jan 2022
Next filing: 06 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PDSB	Common Stock	Options Exercise	$1,442,345	+219,535	+34%	$6.57	866,050	02 Dec 2022	Direct	F2
transaction	PDSB	Common Stock	Tax liability	$1,713,300	-175,184	-20%	$9.78	690,866	02 Dec 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PDSB	Stock Option (Right to Buy)	Options Exercise	$0	-219,535	-100%	$0.000000^*	0	02 Dec 2022	Common Stock	219,535	$6.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This stock option was fully vested in accordance with its terms.
F2	On December 2, 2022, Dr. Bedu-Addo made a net exercise of 219,535 stock options, resulting in his acquisition of 44,351 common shares of the Issuer.